Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing Attracts Billion-Yuan Investment For Health Care Projects

This article was originally published in PharmAsia News

Executive Summary

To accelerate the development of the biopharmaceutical industry, Beijing Municipal Bureau of Industrial Development is stepping up efforts to provide investors with policy consulting and tracking services. The city has this year signed up eight major health care investments totaling 3.83 billion yuan ($548 million). The projects comprise: (1) joint production of MMR (measles, mumps and rubella) vaccines by GSK and Xili Pharmaceutical Group; (2) Genzyme Biotech Beijing's R&D and laboratory production project; (3) Kaizheng Biotech's human blood substitutes and new drug R&D production base; (4) Xiuzheng Pharmaceutical Group's industrial park; (5) Korean Daewoong Pharmaceutical's R&D center and production base; (6) Tiandao Biotech's monoclonal antibody R&D and production base; (7) Mindray's Beijing academic institution; and (8) Genova Biotech's Novaferon production base. (Click here for more - Chinese language)

You may also be interested in...



Korean Daewoong Pharmaceutical Opens R&D Center in India

SEOUL - South Korea's Daewoong Pharmaceutical opened a new research and development center Jan. 20 in the southern India city of Hyderabad as it tries to pave the way for the development of what it called "different generics" and new brand products for the U.S. and European markets

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel